Nursing Elites

1. In emphysema, what features result in impaired oxygenation?

• A. The bronchioles are inflamed and filled with mucus
• B. The alveoli have lost surfactant and collapse
• C. Enlarged, permanently inflated alveoli
• D. The accumulation of purulent fluid in the bronchioles

Correct answer: C

Rationale: The correct answer is C. In emphysema, impaired oxygenation results from enlarged and permanently inflated alveoli, leading to reduced surface area for gas exchange. Choices A, B, and D are incorrect. In emphysema, bronchioles are not typically filled with mucus, alveoli losing surfactant and collapsing is more characteristic of conditions like atelectasis, and purulent fluid accumulation in the bronchioles is commonly seen in conditions like pneumonia, not emphysema.

2. A 55-year-old male patient is taking finasteride (Proscar) for benign prostatic hyperplasia (BPH). What patient teaching should the nurse provide regarding the use of this medication?

• A. Avoid taking over-the-counter antacids while on this medication.
• B. This medication may decrease libido.
• C. This medication may take several months to improve symptoms.
• D. This medication may cause increased hair growth.

Correct answer: C

Rationale: Correct Answer: The nurse should inform the patient that finasteride may take several months to improve symptoms of BPH. It is essential for patients to understand the delayed onset of action to manage their expectations and compliance. Choice A is incorrect because there is no significant interaction between finasteride and over-the-counter antacids. Choice B is incorrect as finasteride is more commonly associated with decreased libido rather than increased libido. Choice D is incorrect as finasteride is known to reduce hair growth rather than increase it.

3. After experiencing several months of worsening nocturia, a patient has been assessed for benign prostatic hypertrophy (BPH) and has begun drug treatment. In addition to nocturia, what other sign or symptom is most likely to accompany BPH?

• A. Hematuria
• B. Erectile dysfunction
• C. Urinary frequency
• D. Flank pain

Correct answer: A

Rationale: The correct answer is hematuria. Hematuria, which is the presence of blood in the urine, is a common sign associated with benign prostatic hypertrophy (BPH). It can occur due to irritation or damage to the prostate tissue. While urinary frequency and erectile dysfunction can also be seen in BPH patients, hematuria is more specifically linked to prostate issues. Flank pain is not typically a direct symptom of BPH.

4. A patient is receiving oral nystatin suspension for a fungal infection of the mouth. Which of the following adverse effects is most likely to be experienced with this form of nystatin?

• A. Local irritation
• B. Burning
• C. Nausea
• D. Urinary urgency

Correct answer: A

Rationale: The correct answer is A: Local irritation. When using oral nystatin suspension for a fungal infection of the mouth, local irritation is the most likely adverse effect that a patient may experience. Nystatin is generally well-tolerated, but some patients may develop local irritation, such as mouth or throat irritation. Choices B, C, and D are less likely adverse effects of oral nystatin suspension. Burning, nausea, and urinary urgency are not commonly associated with nystatin use for a fungal infection of the mouth.

5. A hospital patient's complex medical history includes a recent diagnosis of kidney cancer. Which of the following medications is used to treat metastatic kidney cancer?

• A. Filgrastim (Neupogen)
• B. Aldesleukin (Proleukin)
• C. Interferon alfa-2b (Intron A)
• D. Darbepoetin alfa (Aranesp)

Correct answer: B

Rationale: The correct answer is B: Aldesleukin (Proleukin). Aldesleukin is a medication used in the treatment of metastatic kidney cancer. It is a recombinant interleukin-2 that works by stimulating the immune system to attack cancer cells. Choice A, Filgrastim, is a medication used to stimulate the production of white blood cells. Choice C, Interferon alfa-2b, is used in the treatment of certain cancers but not specifically metastatic kidney cancer. Choice D, Darbepoetin alfa, is used to treat anemia by stimulating red blood cell production and is not indicated for metastatic kidney cancer.

Similar Questions